The 5TMM series: A useful in vivo mouse model of human multiple myeloma

Hematology Journal

Volumn 1, Issue 5, 2000, Pages 351-356

  Asosingh, Kewal ^a   Radl, Jiri ^b   Van Riet, Ivan ^a   Van Camp, Ben ^a   Vanderkerken, Karin ^a  

^a VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^b TNO   (Netherlands)

Author keywords

5TMM; Models; Myeloma

Indexed keywords

CANCER VACCINE; DNA VACCINE; PARAPROTEIN; PRISTANE; TERPENE;

ANIMAL; BAGG ALBINO MOUSE; C57BL MOUSE; CHEMICALLY INDUCED DISORDER; CHROMOSOME ABERRATION; COMPARATIVE STUDY; DISEASE MODEL; GENETICS; HUMAN; MOUSE; MOUSE MUTANT; MULTIPLE MYELOMA; ONCOGENE MYC; OSTEOLYSIS; PARAPROTEINEMIA; PATHOLOGY; PERITONEUM TUMOR; PLASMACYTOMA; REVIEW; VACCINATION; XENOGRAFT;

ANIMALS; CANCER VACCINES; CHROMOSOME ABERRATIONS; DISEASE MODELS, ANIMAL; GENES, MYC; HUMANS; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, SCID; MULTIPLE MYELOMA; MYELOMA PROTEINS; OSTEOLYSIS; PARAPROTEINEMIAS; PERITONEAL NEOPLASMS; PLASMACYTOMA; TERPENES; TRANSPLANTATION, HETEROLOGOUS; VACCINATION; VACCINES, DNA;

EID: 0034584607     PISSN: 14664860     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.thj.6200052     Document Type: Article

References (51)

1. Anderson K. 1998 Multiple myeloma update: new insights and future directions. Seminars in Oncology 26 (Suppl. 13): 1, 1999.
2. Barlogie B, Jagannath S, Epstein J, Munshi N, Siegel D, Desikan KR, Feinman R, Hsu PL, von Bremen K, Tricot G. Biology and therapy of multiple myeloma in 1996. Seminars in Hematology 34 (Suppl. 1): 67, 1997.
3. Bataille R. New insights in the clinical biology of multiple myeloma. Seminars in Hematology 34 (Suppl. 1): 23, 1997.
4. Caligaris-Cappio F, Bergui L, Gregoretti MG, Gaidano G, Gaboli M, Schena M, Zallone AZ, Marchisio PC. Role of bone marrow cells in the growth of human multiple myeloma. Blood 77: 2688, 1991.
5. Klein B, Zhang XG, Jourdan M, Content J, Houssiau F, Aarden L, Piechaczyk M, Bataille R. Paracrine rather than autocrine regulation of myeloma growth and differentiation by interleukin-6. Blood 73: 517, 1989.
6. Lokhorst HM, Lamme T, de Smet M, Klein S, de Weger RA, van Oers R, Bloem AC. Primary tumor cells of myeloma patients induce interleukin-6 secretion in long-term bone marrow cultures. Blood 84: 2269, 1994.
7. Van Riet I, Vanderkerken K, De Greef C, Van Camp B. Homing behaviour of the malignant cell clone in multiple myeloma. Medical Oncology 15: 154, 1998.
8. Uchiyama H, Barut BA, Mohrbacher AF, Chauchan D, Anderson KC. Adhesion of human myeloma-derived cell lines to bone marrow stromal cells stimulates interleukin-6 secretion. Blood 82:3712, 1993.
9. Radl J. Multiple myeloma and related disorders. Pathologie Biologie 47: 109, 1999.
10. Radl J, De Glopper E, Schuit HR, Zurcher C. Idiopathic paraproteinemia. II. Transplantation of the paraprotein-producing clone from old to young C57BL/KaLwRij mice. Journal of Immunology 122: 609, 1979.
11. Radl J, Croese JW, Zurcher Ch, van den Enden-Vieveen MHM, de Leeuw AM. Animal model of human disease: multiple myeloma. American Journal of Pathology 132: 177, 1988.
12. Radl J. Age-related monoclonal gammapathies: Clinical lessons from the aging C57BL mouse. Immunology Today 11: 234, 1990.
13. Radl J, van den Enden-Vieveen MHM, Zurcher C, Roholl PJM, Blauw E. Morbus Waldenström-like B-cell lymphoma in the aging C57BL/KalwRij mouse, p.233 In: Radl J, Van Camp B (ed.) Monoclonal gammapathies II-Clinical significance and basic mechanisms: Topics in aging research in Europe. EURAGE, Rijswijk, 1989.
14. Vanderkerken K, De Raeve H, Van Meirvenne S, Radl J, Van Riet I, Thielemans K, Van Camp B. Organ involvement and phenotypic adhesion profile of 5T2 and 5T33 myeloma cells in the C57BL/KaLwRij mouse. British Journal of Cancer 76: 451, 1997.
15. Croese JW, van den Enden-Vieveen MHM, Zurcher C, Radl J. The C57BL/KaLwRij mouse model of multiple myeloma, p.77. In: Radl J, Van Camp B (eds) Monoclonal gammapathies II-Clinical significance and basic mechanisms: Topics in aging research in Europe. EURAGE, Rijswijk, 1989.
16. Zhu D, van Arkel C, King CA, Van Meirvenne S, De Greef C, Thielemans K, Radl J, Stevenson FK. Immunoglobulin VH gene sequence analysis of spontaneous murine immunoglobulin-secreting B-cell tumors with clinical features of human disease. Immunology 93: 162, 1998.
17. Bakkus MHC, Heirman C, Van Riet I, Van Camp B, Thielemans K. Evidence that multiple myeloma immunoglobulin heavy chain VDJ genes contain somatic mutations but show no intraclonal variations. Blood 80: 2326, 1992.
18. Butcher EC, Picker J. Lymphocyte homing and homeostasis. Science 272: 66, 1996.
19. Vanderkerken K, De Greef C, Asosingh K, Arteta B, De Veerman M, Van Riet I, Kobayashi M, Smedsrod B, Van Camp B. Selective initial in vivo homing pattern of 5T2 multiple myeloma cells in the C57BL/KalwRij mouse. British Journal of Cancer 82: 953, 2000.
20. Vanderkerken K, Asosingh K, Braet F, Van Riet I, Van Camp B. Insulin like growth factor-I acts as a chemoattractant factor for 5T2 multiple myeloma cells. Blood 93: 235, 1999.
21. Vande Broek I, Vanderkerken K, De Greef C, Van Camp B, Van Riet I. CDPGYIGSR, a synthetic nonapeptide from the B1 chain of laminin, modulates the migration of multiple myeloma cells to laminin, VII International Multiple Myeloma Workshop, September 1-5, Stockholm, Sweden, Abstract P135, 1999.
22. Asosingh K, Günthert U, Bakkus MHC, De Raeve H, Goes E, Van Riet I, Van Camp B, Vanderkerken K. In vivo induction of insulin-like growth factor-I receptor and CD44v6 confers homing and adhesion to murine multiple myeloma cells. Cancer Research 60: 3096, 2000.
23. Radl J, Croese JW, Zurcher C, van den Enden-Vieveen HM, Brondijk RJ, Kazil M, Haaijman JJ, Reitsma PH, Bijvoet OLM. Influence of treatment with APD-biphosphonate on the bone lesions in the mouse 5T2 multiple myeloma model. Cancer 55: 1030, 1985.
24. Croese JW, Zurcher C, van den Enden-Vieven MHM, Radl J. Effect of long-term treatment with the bisphosphonate APD on 5T2 mouse multiple myeloma, p. 199. In: Radl J, Van Camp B (eds) Monoclonal gammapathies III-Clinical significance and basic mechanisms: Topics in aging research in Europe. EURAGE, Rijswijk, 1991.
25. Garrett IR, Dallas S, Radl J, Mundy R. A murine model of human myeloma bone disease. Bone 20: 515, 1997.
26. Dallas SL, Garrett A, Oyayobi BO, Dallas MR, Boyce BF, Bauss F, Radl J, Mundy GR. Ibandronate reduces osteolytic lesions but not tumour burden in a murine model of myeloma bone disease. Blood 93: 1697, 1999.
27. Shipman C, Vanderkerken K, Rogers M, Lippit J, Asosingh K, Hughes D, Van Camp B, Russell G, Croucher P. The potent bisphosphonate does not induce myeloma cell apoptosis in a murine model of established multiple myeloma, VII International Multiple Myeloma Workshop, September 1-5, Stockholm, Sweden, Abstract P118, 1999.
28. Vanderkerken K, Goes E, De Raeve H, Radl J, Van Camp B. Follow-up of bone lesions in an experimental multiple myeloma mouse model: description of an in vivo technique using radiography dedicated for mammography. British Journal of Cancer 73: 1463, 1996.
29. Manning LS, Berger JD, O'Donoghue HL, Sheridan GN, Claringbold PG. A model of multiple myeloma: culture of 5T33 murine myeloma cells and evaluation of tumorigenicity in the C57BL/KaLwRij mouse. British Journal of Cancer 66: 1088, 1992.
30. King CA, Spellerberg MB, Zhu D, Rice J, Sahota SS, Thompsett AR, Hamblin TJ, Radl J, Stevenson FK. DNA vaccines with single-chain Fv fused to fragment C of tetanus toxin induce protective immunity against lymphoma and myeloma. Nature Medicine 4: 1281, 1998.
31. van den Akker ThW, Radl J, Franken-Postma E, Hagemeijer A. Cytogenetic findings in mouse multiple myeloma and waldenström's macroglobulinemia. Cancer Genetics and Cytogenetics 86: 156, 1996.
32. Gazdar AF, Oie HK, Kirsch IR, Hollis GF. Establishment and characterization of a human plasma cell myeloma culture having a rearranged cellular myc proto-oncogene. Blood 67: 1542, 1986.
33. Selvanayagam P, Blick M, Naini F, Van Tuinen P, Ledbetter DH, Alexanian R, Saunders GF, Bargolie B. Alteration and abnormal expression of the c-myc oncogene in human multiple myeloma. Blood 71: 30, 1988.
34. Yamada K, Shionoya S, Amano M, Tinamura Y. A Burkitt type 8;14 translocation in a case of plasma cell leukemia. Cancer Genetics and Cytogenetics 9: 67, 1983.
35. Potter, M. Plasmacytomas in mice. Seminars in Oncology 13: 275, 1986.
36. Radl J, Punt YA, van den Enden-Vieveen MHM, Bentvelzen PAJ, Bakkus MHC, van den Akker ThW, Benner R. The 5T mouse multiple myeloma model: absence of c-myc oncogene rearrangement in early transplant generations. British Journal of Cancer 61: 276, 1990.
37. Huang Y, Richardson JA, Tong AW, Zhang B, Stone MJ, Vitetta ES. Disseminated growth of a human multiple myeloma cell line in mice with severe combined immunodeficiency disease. Cancer Research 53: 1392, 1993.
38. Cattan AR, Douglas E. The C.B.17 SCID mouse strain as a model for human disseminated leukaemia and myeloma in vivo. Leukemia Research 18: 513, 1994.
39. Tsunenari T, Koishihara Y, Nakamura A, Moriya M, Ohkawa H, Goto H, Shimazaki C, Nakagawa M, Ohsugi Y, Kishimoto T, Akamatsu K. New xenograft model of multiple myeloma and efficacy of a humanized antibody against human interleukin-6 receptor. Blood 90: 2437, 1997.
40. Hjorth-Hansen H, Seiffert MF, Börset M, Aarset H, Östlie A, Sundan A, Waage A. Marked osteoblastopenia and reduced bone formation in a model of multiple myeloma bone disease in severe combined immunodeficiency mice. Journal of Bone Mineral Research 14: 256, 1999.
41. Alsina M, Boyce B, Devlin RD, Anderson JL, Craig F, Mundy GR, Roodman GD. Development of an in vivo model of human multiple myeloma bone disease. Blood 87: 1495, 1996.
42. Pellat-Deceunynk C, Amiot M, Bataille R, Van Riet I, Van Camp B, Omede P, Boccadoro M. Human myeloma cell lines as a tool for studying the biology of multiple myeloma: a reappraisal 18 years after. Blood 86: 4001, 1995.
43. Feo-Zuppardi FJ, Taylor CW, Iwato K, Lopez MHA, Grogan TM, Odeleye A, Hersh EM, Salmon SE. Long-term engraftment of fresh human myeloma cells in SCID mice. Blood 80: 2843, 1992.
44. Ashmann EJM, van Tol MJD, Oudeman-Gruber J, Lokhorst H, Uytdehaag FGCM, Schuurman H, Bloem AC. The SCID mouse as a model for multiple myeloma. British Journal of Haematology 89: 319, 1995.
45. Rebouissou C, Wijdenes J, Autissier P, Tarte K, Costes V, Liautard J, Rossi J, Brochier J, Klein B. A gp130 interleukin-6 transducer-dependent SCID model of human multiple myeloma. Blood 91: 4727, 1998.
46. Bellamy WT, Odeleye A, Finley P, Hiuzenga B, Dalton WS, Weinstein RS, Hersh EM, Grogan TM. An in vivo model of human multidrug-resistant multiple myeloma in SCID mice. American Journal of Pathology 142: 691, 1993.
47. Pilarski LM, Hipperson G, Seeberger K, Pruski E, Coupland RW, Belch AR. Myeloma progenitors in the blood of patients with aggressive or minimal disease: engraftment and self-renewal of primary human myeloma in the bone marrow of NOD SCID mice. Blood 95: 1056, 2000.
48. Urashima M, Chen BP, Pinkus GS, Bronson RT, Dedera DA, Hoshi Y, Teoh G, Ogata A, Treon SP, Chauhan D, Anderson KC. The development of a model for the homing of multiple myeloma cells to human bone marrow. Blood 90: 754, 1997.
49. Yaccoby S, Barlogie B, Epstein J. Primary myeloma cells growing in SCID-hu mice: a model for studying the biology and treatment of myeloma and its manifestations. Blood 92: 2908, 1998.
50. Sjak-Shie NN, Tsingotjidou AS, Zhang K, Vescio RA, Said JW, Lieberman J, Berenson JR. Development of a SCID-hu animal model that more closely resembles human multiple myeloma. American Society of Hematology 41st annual meeting, Abstract 2447, 1999.
51. Yaccoby S, Epstein J. The proliferation potential of myeloma plasma cells manifest in the SCID-hu host. Blood 94: 3576, 1999.